China developing novel Alzheimer's drugs - by Wang Fangqing
Chinese companies are joining multinationals like Novartis and Eli Lilly to develop novel drugs for Alzheimer’s disease (AD), reports The Pharma Letter’s local correspondent, Wang Fangqing.
The most promising candidate - GV971- is developed by Shanghai Institute of Materia Medica (SIMM), a division of Chinese Academy of Science (ACS. It is currently under Phase III trials in China, said a SIMM spokesperson,
“The candidate is in Phase III studies for a year. We expect it will be introduced to the market as soon as in 2017,” she said, adding this project is government supported. She declined to give more information, saying all clinical data would be released should the studies complete successfully.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze